Patents Assigned to Navrogen, Inc.
  • Publication number: 20210040174
    Abstract: The CA125/MUC16 protein has been found to be a suppressor of humoral immunity, in particularly antibody-mediated humoral immunity. The generation of antagonists that can block its immune suppressive effects on antibodies may lead to enhanced therapeutic responses by antibodies that are negatively impacted by CA125/MUC16. In addition, it offers the ability to unlock humoral immune suppression of a patient's endogenous humoral response that may be suppressed by CA125/MUC16 suppression. CA125/MUC16 antagonists can be used to enhance humoral response of therapeutic antibodies and patients with CA125/MUC16-expressing diseases, including cancer.
    Type: Application
    Filed: August 4, 2020
    Publication date: February 11, 2021
    Applicant: Navrogen, Inc.
    Inventors: Nicholas C. Nicolaides, Luigi Grasso, James Bradford Kline